Sign In
SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK
Author(s): ,
Uwe Platzbecker
Affiliations:
Department of Medicine I,University Hospital Dresden,Dresden,Germany
,
Katharina Götze
Affiliations:
Department of Medicine III,Klinikum rechts der Isar, TUM,Munich,Germany
,
Jan Krönke
Affiliations:
Department of Internal Medicine III,University Hospital Ulm,Ulm,Germany
,
Uta Oelschlägel
Affiliations:
Department of Medicine I,University Hospital Dresden,Dresden,Germany
,
Freya Schulze
Affiliations:
Department of Medicine I,University Hospital Dresden,Dresden,Germany
,
Katja Sockel
Affiliations:
Department of Medicine I,University Hospital Dresden,Dresden,Germany
,
Jan Moritz Middeke
Affiliations:
Department of Medicine I,University Hospital Dresden,Dresden,Germany
,
Fatiha Chermat
Affiliations:
Groupe Francophone des Myélodysplasies,Paris,France
,
Silke Gloaguen
Affiliations:
EMSCO,Dresden,Germany
,
Martin Puttrich
Affiliations:
GWT-TUD GmbH,Dresden,Germany
,
Carmen Weigt
Affiliations:
GWT-TUD GmbH,Dresden,Germany
,
Katja Jersemann
Affiliations:
GWT-TUD GmbH,Dresden,Germany
,
Pierre Fenaux
Affiliations:
Service d'Hématologie seniors,Hôpital Saint-Louis,Paris,France
,
Richard Schlenk
Affiliations:
Nationales Centrum für Tumorerkrankungen (NCT),Heidelberg,Germany
,
Aristoteles Giagounidis
Affiliations:
Dept. for Oncology, Hematology and Palliative Care,Marien Hospital Düsseldorf,Düsseldorf,Germany
Lionel Adès
Affiliations:
Service d'Hématologie seniors,Hôpital Saint-Louis,Paris,France
EHA Library. Platzbecker U.
Jun 16, 2018; 215549
Prof. Dr. Uwe Platzbecker
Prof. Dr. Uwe Platzbecker
Contributions
Abstract

Abstract: PS1245

Type: Poster Presentation

Presentation during EHA23: On Saturday, June 16, 2018 from 17:30 - 19:00

Location: Poster area

Background
AML and MDS patients failing hypomethylating agents (HMA) based therapies have a dismal prognosis highlighting an unmet medical need for these patients. CD123 (Interleukin-3 receptor alpha chain [IL3RA]) is overexpressed in MDS and AML progenitors and seems to be a promising target for immunotherapy. Talacotuzumab (TAL, JNJ-56022473) is an IgG1 monoclonal antibody targeting CD123 preferentially via antibody-dependent cellular cytotoxicity (ADCC). In addition the antibody inhibits IL-3 signaling to impede proliferation of leukemic progenitor cells.

Aims
The SAMBA trial of the German and French MDS study groups within the EMSCO network assessed the safety and efficacy of single agent TAL treatment in patients with higher-risk MDS or AML failing first line treatment with HMAs.

Methods
TAL was given i.v. at a dose of 9mg/kg once every two weeks (14d ± 2d) for a total of 6 infusions and could be continued in responding patients. The study was accompanied by an immune monitoring via flowcytometric analysis to investigate the dispersion of T- and NK cells in blood (PB) and bone marrow (BM) at the time of screening and during therapy in comparison with healthy, age matched controls. Of special importance were NK cells, as they are activated by high-affinity binding by the Fc-region of TAL inducing ADCC at targeted cells.

Results
A total of 24 AML/MDS patients having failed HMA with a median age of 77 years were included (Table 1). Therapy resulted in grade 3/4 infusion related side effects (pneumonia, n=1; infusion-related reaction, n=3; septic shock, n=1) in 4 patients, which led to early study discontinuation. Most frequent severe adverse events observed were infections (38%), cytopenias (9%), cardiac and gastrointestinal (7.5%, each) as well as nervous systems disorders (7.5%) in this older HMA-refractory MDS/AML population. Fourteen patients were assessed for response after 4 infusions and 8 after 6 infusions, respectively. Overall, 5 responders were identified; four AML patients with a marrow partial remission and one with a marrow complete remission; none of the responding patients achieved formal hematological improvement. Duration of response in these patients was short (median 1 month, range 1-6). Three patients are still on treatment based on subjective benefit in two of them despite losing objective response and one MDS patient with disease stabilization. Median survival for the entire cohort of patients is 4.8 months (95%>CI, 2.7–8.7). Prior to therapy, patients already displayed a disturbed immune profile compared to healthy controls. In fact, patients had significantly less mature NK-cells (75% CD56 dim NK-cells in patients vs. 87.9% in controls; p<0.01) including a higher expression of inhibiting (NK-KIR) and less activating (NKG2D and DNAM1) NK-cell receptors (p<0.01).

Conclusion
Even though ADCC-mediated targeting of CD123 seems to be a promising treatment option, patients with advanced MDS/AML displayed significant alterations in their immune cell repertoire which may have contributed to the moderate clinical benefit with single agent TAL treatment.

Session topic: 10. Myelodysplastic syndromes – Clinical

Keyword(s): ADCC, Immune therapy, MDS/AML, NK cell

Premium Sponsors
Major Sponsors

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies